Literature DB >> 7131953

Effect of doxapram on the action of other drugs and the hepatic drug-metabolizing system in mice.

K Sasaki, S Furusawa, G Takayanagi.   

Abstract

Effects of doxapram, a respiratory stimulant, on the action of other drugs and the activity of the hepatic drug-metabolizing enzyme were studied in mice. The hypothermic effect induced by aminopyrine and the muscle relaxant effect induced by meprobamate were potentiated by the pretreatment with doxapram 60 min before. Furthermore, doxapram significantly enhanced the lethalities of picrotoxin and strychnine and the analgesic actions of aminopyrine and morphine. The plasma concentration of aminopyrine or pentobarbital in doxapram-treated mice was higher than those in untreated mice, and the plasma concentration of normustard related to an active metabolite of cyclophosphamide after the administration of cyclophosphamide was lower in doxapram-treated mice. On the other hand, doxapram (50 mg/kg, i.p.) reduced remarkably the activities of aminopyrine N-demethylase and aniline hydroxylase in the hepatic 9,000xg supernatant fraction, and also reduced the cytochrome P-450 contents in hepatic microsomes. However, no significant alteration by doxapram was observed on the activities of NADH-ferricyanide reductase and NADPH-cytochrome c reductase and cytochrome b5 contents. It seems likely that the mechanisms of the interaction between doxapram and combined drugs involved the depression of the hepatic drug-metabolizing system in microsomes and a subsequent variation of drug level in the plasma.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7131953     DOI: 10.1254/jjp.32.699

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  2 in total

1.  Differential antagonism of tetramethylenedisulfotetramine-induced seizures by agents acting at NMDA and GABA(A) receptors.

Authors:  Michael P Shakarjian; Jana Velíšková; Patric K Stanton; Libor Velíšek
Journal:  Toxicol Appl Pharmacol       Date:  2012-09-27       Impact factor: 4.219

Review 2.  Risks and benefits of therapies for apnoea in premature infants.

Authors:  J M Hascoet; I Hamon; M J Boutroy
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.